Galena Biopharma In The News
- Galena Biopharma Completes Over-Enrollment of NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT Clinical Trial
- Galena Biopharma Announces Closing of Over-Allotment Option, Increasing Total Gross Proceeds to $43.7 Million
- Galena Biopharma to Present at the 14th Annual Needham Healthcare Conference
- Galena Biopharma Expands Patient Population in NeuVax(TM) (nelipepimut-S) and trastuzumab Phase 2b Combination Clinical Trial in HER2 1+/2+ Patients
Galena is committed to ensuring eligible patients have access to our products. Learn more at GalenaPatientServices.com.